Antrocin, a bioactive component from Antrodia cinnamomea, suppresses breast carcinogenesis and stemness via downregulation of β-catenin/Notch1/Akt signaling

Jia Hong Chen, Alexander T.H Wu, David T.W Tzeng, Chi Cheng Huang, Yew Min Tzeng, Tsu Yi Chao

Research output: Contribution to journalArticle

Abstract

Background: We identified increased β-catenin and Atk expression was associated with drug resistance and poor prognosis in breast cancer patients using public databases. Antrocin treatment suppressed breast tumorigenesis and stemness properties. Hypothesis/Purpose: We aimed to provide preclinical evidence for antrocin, an active component of Antrodia cinnamomea, as a potential small-molecule drug for treating drug-resistant breast cancer. Methods: Various in vitro assays including SRB, Boyden chamber, colony formation, drug combination index and tumor sphere generation were used to determine the anti-cancer and stemness effects of antrocin. Mouse xenograft models were used to evaluate antrocin's effect in vivo. Results: Antrocin treatment suppressed the viability, migration colony formation and mammosphere generation. Antrocin-mediated anti-cancer effects were associated with the decreased expression of oncogenic and stemness markers such as β-catenin, Akt and Notch1. A sequential regimen of antrocin and paclitaxel synergistically inhibit breast cancer viability in vitro and in vivo. Conclusion: Our preclinical evidence supports antrocin's ability of inhibiting tumorigenic and stemness properties in breast cancer cells. Further develop of antrocin should be encouraged; the combined use of antrocin and paclitaxel may also be considered for future clinical trials.

LanguageEnglish
Pages70-78
Number of pages9
JournalPhytomedicine
Volume52
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Antrodia
Neoplastic Stem Cells
beta Catenin
Drug Resistance
Carcinogenesis
Breast
Down-Regulation
Breast Neoplasms
Paclitaxel
antrocin
Neoplasms
Drug Combinations
Heterografts
Pharmaceutical Preparations

Keywords

  • Antrocin
  • Antrodia cinnamomea
  • Breast cancer
  • Cancer stem cells
  • Drug resistance

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery
  • Complementary and alternative medicine

Cite this

Antrocin, a bioactive component from Antrodia cinnamomea, suppresses breast carcinogenesis and stemness via downregulation of β-catenin/Notch1/Akt signaling. / Chen, Jia Hong; T.H Wu, Alexander; T.W Tzeng, David; Huang, Chi Cheng; Tzeng, Yew Min; Chao, Tsu Yi.

In: Phytomedicine, Vol. 52, 01.01.2019, p. 70-78.

Research output: Contribution to journalArticle

Chen, Jia Hong ; T.H Wu, Alexander ; T.W Tzeng, David ; Huang, Chi Cheng ; Tzeng, Yew Min ; Chao, Tsu Yi. / Antrocin, a bioactive component from Antrodia cinnamomea, suppresses breast carcinogenesis and stemness via downregulation of β-catenin/Notch1/Akt signaling. In: Phytomedicine. 2019 ; Vol. 52. pp. 70-78.
@article{8485b7385e5e4a81964b5eb759604a66,
title = "Antrocin, a bioactive component from Antrodia cinnamomea, suppresses breast carcinogenesis and stemness via downregulation of β-catenin/Notch1/Akt signaling",
abstract = "Background: We identified increased β-catenin and Atk expression was associated with drug resistance and poor prognosis in breast cancer patients using public databases. Antrocin treatment suppressed breast tumorigenesis and stemness properties. Hypothesis/Purpose: We aimed to provide preclinical evidence for antrocin, an active component of Antrodia cinnamomea, as a potential small-molecule drug for treating drug-resistant breast cancer. Methods: Various in vitro assays including SRB, Boyden chamber, colony formation, drug combination index and tumor sphere generation were used to determine the anti-cancer and stemness effects of antrocin. Mouse xenograft models were used to evaluate antrocin's effect in vivo. Results: Antrocin treatment suppressed the viability, migration colony formation and mammosphere generation. Antrocin-mediated anti-cancer effects were associated with the decreased expression of oncogenic and stemness markers such as β-catenin, Akt and Notch1. A sequential regimen of antrocin and paclitaxel synergistically inhibit breast cancer viability in vitro and in vivo. Conclusion: Our preclinical evidence supports antrocin's ability of inhibiting tumorigenic and stemness properties in breast cancer cells. Further develop of antrocin should be encouraged; the combined use of antrocin and paclitaxel may also be considered for future clinical trials.",
keywords = "Antrocin, Antrodia cinnamomea, Breast cancer, Cancer stem cells, Drug resistance",
author = "Chen, {Jia Hong} and {T.H Wu}, Alexander and {T.W Tzeng}, David and Huang, {Chi Cheng} and Tzeng, {Yew Min} and Chao, {Tsu Yi}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.phymed.2018.09.213",
language = "English",
volume = "52",
pages = "70--78",
journal = "Phytomedicine",
issn = "0944-7113",
publisher = "Urban und Fischer Verlag Jena",

}

TY - JOUR

T1 - Antrocin, a bioactive component from Antrodia cinnamomea, suppresses breast carcinogenesis and stemness via downregulation of β-catenin/Notch1/Akt signaling

AU - Chen, Jia Hong

AU - T.H Wu, Alexander

AU - T.W Tzeng, David

AU - Huang, Chi Cheng

AU - Tzeng, Yew Min

AU - Chao, Tsu Yi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: We identified increased β-catenin and Atk expression was associated with drug resistance and poor prognosis in breast cancer patients using public databases. Antrocin treatment suppressed breast tumorigenesis and stemness properties. Hypothesis/Purpose: We aimed to provide preclinical evidence for antrocin, an active component of Antrodia cinnamomea, as a potential small-molecule drug for treating drug-resistant breast cancer. Methods: Various in vitro assays including SRB, Boyden chamber, colony formation, drug combination index and tumor sphere generation were used to determine the anti-cancer and stemness effects of antrocin. Mouse xenograft models were used to evaluate antrocin's effect in vivo. Results: Antrocin treatment suppressed the viability, migration colony formation and mammosphere generation. Antrocin-mediated anti-cancer effects were associated with the decreased expression of oncogenic and stemness markers such as β-catenin, Akt and Notch1. A sequential regimen of antrocin and paclitaxel synergistically inhibit breast cancer viability in vitro and in vivo. Conclusion: Our preclinical evidence supports antrocin's ability of inhibiting tumorigenic and stemness properties in breast cancer cells. Further develop of antrocin should be encouraged; the combined use of antrocin and paclitaxel may also be considered for future clinical trials.

AB - Background: We identified increased β-catenin and Atk expression was associated with drug resistance and poor prognosis in breast cancer patients using public databases. Antrocin treatment suppressed breast tumorigenesis and stemness properties. Hypothesis/Purpose: We aimed to provide preclinical evidence for antrocin, an active component of Antrodia cinnamomea, as a potential small-molecule drug for treating drug-resistant breast cancer. Methods: Various in vitro assays including SRB, Boyden chamber, colony formation, drug combination index and tumor sphere generation were used to determine the anti-cancer and stemness effects of antrocin. Mouse xenograft models were used to evaluate antrocin's effect in vivo. Results: Antrocin treatment suppressed the viability, migration colony formation and mammosphere generation. Antrocin-mediated anti-cancer effects were associated with the decreased expression of oncogenic and stemness markers such as β-catenin, Akt and Notch1. A sequential regimen of antrocin and paclitaxel synergistically inhibit breast cancer viability in vitro and in vivo. Conclusion: Our preclinical evidence supports antrocin's ability of inhibiting tumorigenic and stemness properties in breast cancer cells. Further develop of antrocin should be encouraged; the combined use of antrocin and paclitaxel may also be considered for future clinical trials.

KW - Antrocin

KW - Antrodia cinnamomea

KW - Breast cancer

KW - Cancer stem cells

KW - Drug resistance

UR - http://www.scopus.com/inward/record.url?scp=85055940835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055940835&partnerID=8YFLogxK

U2 - 10.1016/j.phymed.2018.09.213

DO - 10.1016/j.phymed.2018.09.213

M3 - Article

VL - 52

SP - 70

EP - 78

JO - Phytomedicine

T2 - Phytomedicine

JF - Phytomedicine

SN - 0944-7113

ER -